Last reviewed · How we verify
NCT05273489
Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases.
trial testing Hepatectomy in Colorectal Cancer Metastatic in 170 participants. Completed in 31 October 2021.
31 December 2020
Quick facts
| Lead sponsor | Hospital Maciel |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 170 |
| Start date | 1 January 2004 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 October 2021 |
Drugs / interventions tested
- Hepatectomy
Conditions studied
- Colorectal Cancer Metastatic — all drugs for Colorectal Cancer Metastatic →
- Liver Metastases — all drugs for Liver Metastases →
Sponsor
Hospital Maciel
Who can join
18 and older, any sex, with Colorectal Cancer Metastatic or Liver Metastases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Retrospective analysis of a prospectively collected database of 170 patients between 2004 and 2020, who underwent liver resections for CRLM (colorectal liver metastases) at The Queen Elizabeth Hospital trying to determine rates and patterns of recurrence following liver resections for CRLM and concurrently, characterise clinical, pathological and treatment-related factors that could function as predictors of recurrence or survival, particularly neoadjuvant chemotherapy and tumour clearance.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05273489
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hepatectomy
Trials testing the same drug.
- NCT06559761 — Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research · recruiting
- NCT05471674 — Neoadjuvant Anti-PD1 in HCC · Phase 2 · completed
- NCT03844750 — Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases · Phase 2 · terminated
- NCT04705194 — Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging · unknown
- NCT03614546 — Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma · NA · unknown
Other recruiting trials for Colorectal Cancer Metastatic
Currently open trials in the same condition.
- NCT07328087 — COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer · EARLY_PHASE1 · recruiting
- NCT07462650 — Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer · Phase 1, PHASE2 · recruiting
- NCT07193862 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Meta · EARLY_PHASE1 · recruiting
- NCT07172282 — INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases · EARLY_PHASE1 · recruiting
- NCT06889610 — A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05273489 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Maciel
- Last refreshed: 10 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05273489.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing